In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1217-1223

  Rosborough, Terry K ^a  

^a ABBOTT NORTHWESTERN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN;

ACCURACY; ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; DOSE CALCULATION; DRUG ACTIVITY; FEMALE; HEPARINIZATION; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PLASMA VOLUME; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOCRIT; HEPARIN; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0031784749     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Juhan-Vague I, Riera H, Ailaud MF, Verdet D, Sambuc R. Measurement of blood heparin levels - variation in results with assay method. Thromb Haemost 1982;47:295.
2. Marci CD, Prager D. A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 1993;99:546-50.
3. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deyken D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(4 suppl):258s-75.
4. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-5.
5. Elliott CG, Michoki RJ, Brown R, Ottesen OE. Heparin requirements in pulmonary embolism and venous thrombosis: a prospective study. J Clin Pharmacol 1982;22:102-9.
6. Hattersley PG, Mitsuoka JC, Ignoffo RJ, King JH, Musallam NA. Adjusting heparin infusion rates from the initial response to activated coagulation time. Drug Intell Clin Pharm 1983;17:632-4.
7. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993;119:874-81.
8. Shalansky KF, FitzGerald JM, Sunderji R, et al. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy 1996;16:1076-84.
9. Beermann B, Lahnborg G. Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. Thromb Haemost 1981;45:24-6.
10. Cipolle RJ, Seifert RD, Neilan BA, Saske DE, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-93.
11. Wilson JE, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med 1981;70:808-16.
12. Groce JB, Gal P, Douglas JB, Steuterman MC. Heparin dosage adjustment in patients with deep vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Clin Pharm 1987;6:216-22.
13. Kershaw B, White RH, Mungall D, Van Houten J, Brettfeld S. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service. Arch Intern Med 1994;154:1005-11.
14. Estes JW, Pelikan EW, Kruger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clin Pharmacol Ther 1969;10:329-37.
15. Estes JW, Poulin PF. Pharmacokinetics of heparin. Distribution and elimination. Thromb Diathesis Haemorrhage 1974;33:26-37.
16. Perry PM, Herran GR, King JC. Heparin half-life in normal and impaired renal function. Clin Pharmacol Ther 1974;16:514-19.
17. Estes JW. The fate of heparin in the body. Curr Ther Res Clin Exp 1975;18:45-7.
18. Chenella FC, Gill MA, Kern JW, Floyd RA, McGehee WG. Improved method for estimating initial heparin infusion rates. Am J Hosp Pharm 1979;36:782-4.
19. Talstad I. Heparin therapy adjusted for body weight. Am J Clin Pathol 1985;83:378-81.
20. Allen TH, Peng MT, Chen KP, Huang TF, Chang C, Fang HS. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 1956;5:328-45.
21. Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989;8:65-8.
22. Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Ariet M. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 1983;40:1016-19.
23. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10
26. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Results from the GUSTO-I trial. Circulation 1996;93:870-8.
27. Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med 1997;157:2475-9.
28. Rosborough TK. Comparison of antifactor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol 1997;108:662-8.
29. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998;158: 1140-3.
30. de Takats G. Heparin tolerance. A test of the clotting mechanism. Surg Gynecol Obstet 1943;77:31-9.
31. Estes JW. The heterogeneity of the anticoagulant response to heparin. J Clin Pathol 1972;25:45.
32. Saya FG, Coleman LT, Martinoff JT. Pharmacist-directed heparin therapy using a standard dosing and monitoring protocol. Am J Hosp Pharm 1985;42:1965-9.
33. Chenella FC, Klotz TA, Gill MA, et al. Blood sampling strategy for monitoring continuous intravenous heparin therapy. Clin Pharm 1986;5:510-13.
34. Schaefer DC, Hufnagle J, Williams L. Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician 1996;54:2517-21.
35. Wright RR, Tone M, Pollycove M. Blood volume. Semin Nucl Med 1975;5:63-78.
36. Campbell RC, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med 1997;156:857-60.
37. Lijnen HR, Hoylaerts M, Colleen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983;258:3803-8.
38. Levine SP, Sorenson RR, Harris MA, Knierem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol 1984;57:585-96.
39. Preissner KT, Muller-Berghaus G. Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. J Biol Chem 1987;262:12247-53.
40. Young E, Prins MH, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-43.